AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20651608 — intervention group
Group type: COMPARATOR
Intervention: Control group (C) - did not train but performed all exercise tests; CK and LDH measured at 3 time points only.
Number of subjects: 17
Study 19415289 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidetector CT after oral administration of polyethylene glycol solution (n = 21)
Number of subjects: 34
Study 19415289 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidetector CT after administration of methylcellulose via nasojejunal tube (n = 13)
Number of subjects: 34
Study 19415289 — intervention group
Group type: COMPARATOR
Intervention: Endoscopy
Number of subjects: 34
Study 16893664 — intervention group
Group type: EXPERIMENTAL
Intervention: Aneurysm patients without previous related hospitalisation
Number of subjects: 4816
Study 16893664 — intervention group
Group type: EXPERIMENTAL
Intervention: Aneurysm patients with previous hospitalisation for pulmonary causes
Number of subjects: 4816
Study 15145874 — intervention group
Group type: EXPERIMENTAL
Intervention: AAIR pacing (n = 54)
Number of subjects: 177
Study 15145874 — intervention group
Group type: COMPARATOR
Intervention: DDDR with short rate adaptive AV delay (DDDR-s) (n = 60)
Number of subjects: 177
Study 15145874 — intervention group
Group type: COMPARATOR
Intervention: DDDR with fixed long AV delay (DDDR-l) (n = 63)
Number of subjects: 177
Study 15145874 — intervention group
Group type: EXPERIMENTAL
Intervention: Brady-tachy syndrome
Number of subjects: 177
Study 15145874 — intervention group
Group type: EXPERIMENTAL
Intervention: Thromboembolic event before pacemaker implantation
Number of subjects: 177
Study 11162695 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position CT myelography
Number of subjects: 21
Study 11162695 — intervention group
Group type: COMPARATOR
Intervention: Supine position CT myelography
Number of subjects: 21
Study 9782018 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin-bonded Dacron grafts (n=123)
Number of subjects: 257
Study 9782018 — intervention group
Group type: COMPARATOR
Intervention: Control group (unbonded Dacron grafts, n=134)
Number of subjects: 257
Study 8872373 — intervention group
Group type: EXPERIMENTAL
Intervention: Optisol
Number of subjects: 20
Study 8872373 — intervention group
Group type: COMPARATOR
Intervention: H-Sol
Number of subjects: 20
Study 8872373 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Optisol and H-Sol
Number of subjects: 20
Study 1700077 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin plus vinblastine plus bleomycin (PVB) chemotherapy
Number of subjects: 47
Study 1700077 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin plus etoposide (VP-16)
Number of subjects: 47
Study 1700077 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin plus VP-16 plus bleomycin (PVP16B)
Number of subjects: 47
Study 1700077 — intervention group
Group type: COMPARATOR
Intervention: PVB
Number of subjects: 47
Study 1700077 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage chemotherapy
Number of subjects: 47
Study 7377916 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (20 mg, intravenous)
Number of subjects: 20
Study 7377916 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30783957 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen 5% cream
Number of subjects: 66
Study 30783957 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 31708152 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-trimoxazole (20 mg trimethoprim and 100 mg sulfamethoxazole orally for infants <6 months or <5 kg; 40 mg trimethoprim and 200 mg sulfamethoxazole orally for infants >6 months or >5 kg)
Number of subjects: 1219
Study 31708152 — intervention group
Group type: COMPARATOR
Intervention: No co-trimoxazole
Number of subjects: 1219
Study 28917377 — intervention group
Group type: EXPERIMENTAL
Intervention: Beeswax, olive oil and Alkanna tinctoria mixture
Number of subjects: 64
Study 28917377 — intervention group
Group type: COMPARATOR
Intervention: Control group routine dressing
Number of subjects: 64
Study 27370878 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirfenidone (801 mg/day titrated to 2403 mg/day over 16 weeks)
Number of subjects: 63
Study 27370878 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirfenidone with 2-week titration
Number of subjects: 63
Study 27370878 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirfenidone with 4-week titration
Number of subjects: 63
Study 27370878 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirfenidone with concomitant Mycophenolate mofetil (MMF)
Number of subjects: 63
Study 27370878 — intervention group
Group type: EXPERIMENTAL
Intervention: Exploratory disease outcomes
Number of subjects: 63
Study 24634424 — intervention group
Group type: EXPERIMENTAL
Intervention: Tactile stimulation (rubbing the skin adjacent to the injection site or applying pressure)
Number of subjects: 121
Study 24634424 — intervention group
Group type: COMPARATOR
Intervention: No tactile stimulation (control)
Number of subjects: 121
Study 23241431 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous vagus nerve stimulation (tVNS)
Number of subjects: 120
Study 23241431 — intervention group
Group type: COMPARATOR
Intervention: Sham transcutaneous vagus nerve stimulation (sham tVNS)
Number of subjects: 120
Study 20669666 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary administering of 10 mL (0.5 mg) tirofiban and 400 mg XST, followed by 36 h continuous intravenous dripping of tirofiban 10 mL/h and 400 mg XST in 250 mL of saline for dripping.
Number of subjects: 39
Study 20669666 — intervention group
Group type: COMPARATOR
Intervention: Intracoronary administering of 10 mL (0.5 mg) tirofiban, followed by 36 h continuous intravenous dripping of tirofiban 10 mL/h without XST.
Number of subjects: 39
Study 17442201 — intervention group
Group type: EXPERIMENTAL
Intervention: Janus stent (n = 100)
Number of subjects: 200
Study 17442201 — intervention group
Group type: COMPARATOR
Intervention: Tecnic Carbostent (bare metal stent, n = 100)
Number of subjects: 200
Study 17442201 — intervention group
Group type: COMPARATOR
Intervention: Tecnic Carbostent
Number of subjects: 200
Study 17442201 — intervention group
Group type: EXPERIMENTAL
Intervention: Janus stent
Number of subjects: 200
Study 17442201 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 200
Study 16253721 — intervention group
Group type: EXPERIMENTAL
Intervention: Nephrologist A's urinalysis (UA)
Number of subjects: 26
Study 16253721 — intervention group
Group type: COMPARATOR
Intervention: Clinical laboratory UA report reviewed by Nephrologist B
Number of subjects: 26
Study 16253721 — intervention group
Group type: COMPARATOR
Intervention: Clinical laboratory UA report reviewed by Nephrologist A
Number of subjects: 26
Study 16253721 — intervention group
Group type: EXPERIMENTAL
Intervention: Nephrologist B reviewing UA reports from Nephrologist A
Number of subjects: 26
Study 16253721 — intervention group
Group type: EXPERIMENTAL
Intervention: Nephrologist A's review of urine sediment
Number of subjects: 26
Study 16253721 — intervention group
Group type: EXPERIMENTAL
Intervention: Nephrologist A's report of renal tubular epithelial (RTE) cells
Number of subjects: 26
Study 16253721 — intervention group
Group type: EXPERIMENTAL
Intervention: Nephrologist A's report of granular casts
Number of subjects: 26
Study 16253721 — intervention group
Group type: EXPERIMENTAL
Intervention: Nephrologist A's report of hyaline casts
Number of subjects: 26
Study 16253721 — intervention group
Group type: EXPERIMENTAL
Intervention: Nephrologist A's report of RTE casts
Number of subjects: 26
Study 16253721 — intervention group
Group type: EXPERIMENTAL
Intervention: Nephrologist A's report of dysmorphic red blood cells
Number of subjects: 26
Study 16253721 — intervention group
Group type: COMPARATOR
Intervention: Clinical laboratory report of squamous cells
Number of subjects: 26
Study 12164876 — intervention group
Group type: EXPERIMENTAL
Intervention: ET‐A receptor antagonist BQ‐123 (40 nmol/min)
Number of subjects: 2
Study 12164876 — intervention group
Group type: EXPERIMENTAL
Intervention: ET‐B receptor antagonist BQ‐788 (1 and 50 nmol/min)
Number of subjects: 2
Study 12164876 — intervention group
Group type: EXPERIMENTAL
Intervention: BQ‐123 plus BQ‐788 (50 nmol/min)
Number of subjects: 2
Study 12164876 — intervention group
Group type: EXPERIMENTAL
Intervention: ET (5 pmol/min)
Number of subjects: 2
Study 12164876 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine and norepinephrine
Number of subjects: 2
Study 9205027 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric left ventricular hypertrophy
Number of subjects: 0
Study 9205027 — intervention group
Group type: COMPARATOR
Intervention: Other geometric patterns
Number of subjects: 0
Study 8352038 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver acetate mouth spray, used every 2 hours for 3 weeks
Number of subjects: 42
Study 8352038 — intervention group
Group type: COMPARATOR
Intervention: Placebo spray, used every 2 hours for 3 weeks
Number of subjects: 42
Study 3676054 — intervention group
Group type: EXPERIMENTAL
Intervention: HFJV using a frequency of 100 b.p.m. via a proximal injector cannula
Number of subjects: 14
Study 3676054 — intervention group
Group type: COMPARATOR
Intervention: HFJV using three frequencies (100, 300 and 600 b.p.m.) via a 1.8‐mm i.d. proximal injector cannula (proximal injection)
Number of subjects: 14
Study 30173835 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) with a continuous beam 660-nm, 75-mW laser applied for 15 seconds at 8 points for a total treatment time of 2 minutes.
Number of subjects: 20
Study 30173835 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (control group).
Number of subjects: 20
Study 26762525 — intervention group
Group type: EXPERIMENTAL
Intervention: Cangrelor
Number of subjects: 11145
Study 26762525 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 11145
Study 25044172 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with language training
Number of subjects: 290
Study 25044172 — intervention group
Group type: COMPARATOR
Intervention: Speech and language therapy (SLT) alone
Number of subjects: 290
Study 22966124 — intervention group
Group type: EXPERIMENTAL
Intervention: artesunate-primaquine
Number of subjects: 433
Study 22966124 — intervention group
Group type: EXPERIMENTAL
Intervention: primaquine
Number of subjects: 433
Study 20337203 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal electrical stimulation (IVES)
Number of subjects: 26
Study 20337203 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 18216565 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT lens wear
Number of subjects: 20
Study 18216565 — intervention group
Group type: EXPERIMENTAL
Intervention: CRTH lens wear
Number of subjects: 20
Study 18216565 — intervention group
Group type: COMPARATOR
Intervention: Control eyes
Number of subjects: 20
Study 15811140 — intervention group
Group type: EXPERIMENTAL
Intervention: DZX 100 mg three times daily for 6 days
Number of subjects: 12
Study 15811140 — intervention group
Group type: EXPERIMENTAL
Intervention: DZX 50 mg three times daily for 6 days
Number of subjects: 12
Study 15811140 — intervention group
Group type: EXPERIMENTAL
Intervention: DZX 75 mg three times daily for 6 days
Number of subjects: 12
Study 15811140 — intervention group
Group type: EXPERIMENTAL
Intervention: DZX 50 mg in non-obese men
Number of subjects: 12
Study 15811140 — intervention group
Group type: EXPERIMENTAL
Intervention: DZX 100 mg in non-obese men
Number of subjects: 12
Study 15811140 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 11989838 — intervention group
Group type: EXPERIMENTAL
Intervention: Butyrate (100 mM) enema for 8 weeks
Number of subjects: 11
Study 11989838 — intervention group
Group type: COMPARATOR
Intervention: Placebo enema for 8 weeks
Number of subjects: 11
Study 10521743 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 6
Study 10521743 — intervention group
Group type: COMPARATOR
Intervention: Labetalol
Number of subjects: 6
Study 7567409 — intervention group
Group type: EXPERIMENTAL
Intervention: Accurate feedback
Number of subjects: 0
Study 7567409 — intervention group
Group type: COMPARATOR
Intervention: Inaccurate feedback (overestimate)
Number of subjects: 0
Study 7567409 — intervention group
Group type: COMPARATOR
Intervention: Inaccurate feedback (underestimate)
Number of subjects: 0
Study 2065699 — intervention group
Group type: EXPERIMENTAL
Intervention: Liv.52
Number of subjects: 9
Study 2065699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 6853873 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment program (4 weeks of coping-skills training using behavioral rehearsal and self-instruction training)
Number of subjects: 41
Study 6853873 — intervention group
Group type: COMPARATOR
Intervention: Non-treatment control group
Number of subjects: 41
Study 31347247 — intervention group
Group type: EXPERIMENTAL
Intervention: TEA + DBT + ESO (group B)
Number of subjects: 21
Study 31347247 — intervention group
Group type: COMPARATOR
Intervention: Sham-TEA + DBT + ESO (group C)
Number of subjects: 21
Study 31347247 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole (ESO, 20 mg bid) (group A)
Number of subjects: 21
Study 28619486 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-depth-of-focus prototypes (EDOF)
Number of subjects: 43
Study 25644375 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led discharge planning program for childhood asthma management
Number of subjects: 120
Study 24406025 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 0.25mg BID for 2 weeks, then 0.5mg BID for 10 weeks
Number of subjects: 21
Study 24406025 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of ondansetron
Number of subjects: 21
Study 23131371 — intervention group
Group type: EXPERIMENTAL
Intervention: Monochord (MC) sounds
Number of subjects: 40
Study 23131371 — intervention group
Group type: COMPARATOR
Intervention: Progressive muscle relaxation (PMR)
Number of subjects: 40
Study 20574649 — intervention group
Group type: EXPERIMENTAL
Intervention: ETN 25 mg twice a week and MTX 6‐8 mg/week (E + M group)
Number of subjects: 151
Study 20574649 — intervention group
Group type: COMPARATOR
Intervention: ETN alone (E group)
Number of subjects: 151
Study 17310130 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine 20 mg/day orally for 7 days
Number of subjects: 28
Study 17310130 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 15883634 — intervention group
Group type: EXPERIMENTAL
Intervention: Fok1 polymorphism of the VDR
Number of subjects: 99
Study 15883634 — intervention group
Group type: EXPERIMENTAL
Intervention: Fok1 polymorphism of the VDR with Ca intake >800 mg/day
Number of subjects: 99
Study 15883634 — intervention group
Group type: EXPERIMENTAL
Intervention: Fok1 polymorphism of the VDR with Ca intake <= 800 mg/day
Number of subjects: 99
Study 15883634 — intervention group
Group type: EXPERIMENTAL
Intervention: Fok1 genotype (ff)
Number of subjects: 99
Study 12379164 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in systolic blood pressure
Number of subjects: 0
Study 12379164 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased pulse pressure
Number of subjects: 0
Study 12379164 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in pulse pressure
Number of subjects: 0
Study 9665234 — intervention group
Group type: EXPERIMENTAL
Intervention: First RNMI in the first year after index infarction
Number of subjects: 3867
Study 9665234 — intervention group
Group type: EXPERIMENTAL
Intervention: First RNMI in the second year after index infarction
Number of subjects: 3867
Study 9665234 — intervention group
Group type: EXPERIMENTAL
Intervention: First RNMI in the third year after index infarction
Number of subjects: 3867
Study 9665234 — intervention group
Group type: EXPERIMENTAL
Intervention: First RNMI in the fourth year after index infarction
Number of subjects: 3867
Study 9665234 — intervention group
Group type: COMPARATOR
Intervention: Comparison of all groups
Number of subjects: 3867
Study 9764869 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol/exercise regimen
Number of subjects: 39
Study 2750862 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotaped instruction (25-minute videotape demonstrating the Milani-Comparetti Motor Development Screening Test)
Number of subjects: 23
Study 2750862 — intervention group
Group type: COMPARATOR
Intervention: Live instruction (information provided by an instructor)
Number of subjects: 23
Study 2750862 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups rated the learning experience as good.
Number of subjects: 23
Study 681534 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic suggestion (feedback indicating they could remain calm and relaxed)
Number of subjects: 0
Study 681534 — intervention group
Group type: COMPARATOR
Intervention: No therapeutic suggestion (no feedback given)
Number of subjects: 0
Study 681534 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to stressful situation (threat)
Number of subjects: 0
Study 681534 — intervention group
Group type: COMPARATOR
Intervention: No exposure to stressful situation (no threat)
Number of subjects: 0
Study 31821750 — intervention group
Group type: EXPERIMENTAL
Intervention: Itacitinib (10-300 mg, 500 mg, 1000 mg)
Number of subjects: 24
Study 31821750 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 31196032 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide 160 mg PO once daily for 6 months during SRT
Number of subjects: 0
Study 31196032 — intervention group
Group type: EXPERIMENTAL
Intervention: SRT with enzalutamide
Number of subjects: 0
Study 31196032 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28513555 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (400 IU/day)
Number of subjects: 0
Study 28513555 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention (control group)
Number of subjects: 0
Study 25719991 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab plus prompt or deferred focal/grid laser treatment
Number of subjects: 582
Study 25719991 — intervention group
Group type: COMPARATOR
Intervention: Sham injection plus focal/grid laser treatment
Number of subjects: 582
Study 22899589 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stents (ZES)
Number of subjects: 2645
Study 22899589 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 2645
Study 22899589 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-eluting stents (PES)
Number of subjects: 2645
Study 20213132 — intervention group
Group type: EXPERIMENTAL
Intervention: Colpexin Sphere with pelvic floor muscle exercise
Number of subjects: 50
Study 20213132 — intervention group
Group type: COMPARATOR
Intervention: Pelvic floor exercise only
Number of subjects: 50
Study 19088159 — intervention group
Group type: COMPARATOR
Intervention: Testosterone (Te) / Placebo
Number of subjects: 42
Study 19088159 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone (Te) / Dutasteride
Number of subjects: 42
Study 19088159 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone (Te) / Anastrozole
Number of subjects: 42
Study 19088159 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone (Te)
Number of subjects: 42
Study 19088159 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone (Te) and Estradiol (E(2))
Number of subjects: 42
Study 19088159 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydrotestosterone (DHT)
Number of subjects: 42
Study 16438751 — intervention group
Group type: EXPERIMENTAL
Intervention: Parecoxib 40 mg intravenously 3 min before induction of anaesthesia
Number of subjects: 68
Study 16438751 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 68
Study 12780746 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein containing isoflavones
Number of subjects: 106
Study 12780746 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 10701612 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiviral therapy
Number of subjects: 59
Study 10701612 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained virologic responders
Number of subjects: 59
Study 10701612 — intervention group
Group type: COMPARATOR
Intervention: Non-responders
Number of subjects: 59
Study 9354348 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 800 mg daily
Number of subjects: 50
Study 9354348 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 8222508 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II (low dose: 1 ng min-1kg-1)
Number of subjects: 12
Study 8222508 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II (high dose: 5 ng min-1kg-1)
Number of subjects: 12
Study 8222508 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2419383 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially purified cat- or dog-dander extracts
Number of subjects: 39
Study 2419383 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 31898758 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG biofeedback therapy applied to tibialis anterior muscles, 5 days a week for 3 weeks in addition to conventional physiotherapy
Number of subjects: 40
Study 31898758 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapy applications
Number of subjects: 40
Study 30956111 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass drug administration of ivermectin (200 μg/kg) and azithromycin (20 mg/kg)
Number of subjects: 26188
Study 30956111 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass drug administration of ivermectin and azithromycin
Number of subjects: 26188
Study 27858150 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 cups of study coffee
Number of subjects: 160
Study 27858150 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 cups of study coffee
Number of subjects: 160
Study 27858150 — intervention group
Group type: COMPARATOR
Intervention: Water (placebo)
Number of subjects: 160
Study 27840352 — intervention group
Group type: EXPERIMENTAL
Intervention: Pipemidic acid (400 mg bid)
Number of subjects: 80
Study 27840352 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenazopyridine (200 mg tid)
Number of subjects: 80
Study 27840352 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium diclofenac (50 mg bid)
Number of subjects: 80
Study 27840352 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 80